Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer.

Park JS, Lim JY, Park SK, Kim MK, Ko HS, Yoon SO, Kim JW, Choi SH, Cho JY.

Cancer Res Treat. 2011 Dec;43(4):236-43. doi: 10.4143/crt.2011.43.4.236. Epub 2011 Dec 27.

PMID:
22247709
[PubMed]
Free PMC Article
2.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
3.

Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28.

PMID:
20878159
[PubMed - indexed for MEDLINE]
4.

Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK.

Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2.

PMID:
18391599
[PubMed - indexed for MEDLINE]
5.

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer.

Jeon EK, Hong SH, Kim TH, Jung SE, Park JC, Won HS, Ko YH, Rho SY, Hong YS.

Cancer Res Treat. 2011 Sep;43(3):148-53. doi: 10.4143/crt.2011.43.3.148. Epub 2011 Sep 30.

PMID:
22022291
[PubMed]
Free PMC Article
6.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC.

J Clin Oncol. 2009 Jun 10;27(17):2848-54. doi: 10.1200/JCO.2008.20.4552. Epub 2009 Apr 20.

PMID:
19380443
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A.

Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19.

PMID:
19153116
[PubMed - indexed for MEDLINE]
Free Article
8.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
[PubMed - indexed for MEDLINE]
9.

Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.

Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N.

Med Oncol. 2014 Sep;31(9):153. doi: 10.1007/s12032-014-0153-y. Epub 2014 Aug 7.

PMID:
25099765
[PubMed - in process]
10.

The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.

Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R.

Tumori. 2000 Nov-Dec;86(6):465-9.

PMID:
11218187
[PubMed - indexed for MEDLINE]
11.

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

Douillard JY, Sobrero A, Carnaghi C, Comella P, Díaz-Rubio E, Santoro A, Van Cutsem E.

Ann Oncol. 2003;14 Suppl 2:ii7-12. Review.

PMID:
12810451
[PubMed - indexed for MEDLINE]
Free Article
12.

[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].

Li J, Xu JM, Li J, Zhang XD, Bai Y, Chu YP, Wang YH, Liu DQ, Jin ML, Shen L.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):225-7. Chinese.

PMID:
18756942
[PubMed - indexed for MEDLINE]
13.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A.

J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 2.

PMID:
14657227
[PubMed - indexed for MEDLINE]
Free Article
14.

Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.

Kucukzeybek Y, Dirican A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Medeni M, Tarhan MO.

Asian Pac J Cancer Prev. 2012;13(6):2771-4.

PMID:
22938457
[PubMed - indexed for MEDLINE]
Free Article
15.

Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.

Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, Ki Lee W, Chung M.

Anticancer Drugs. 2005 Jul;16(6):621-5.

PMID:
15930889
[PubMed - indexed for MEDLINE]
16.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

PMID:
17346499
[PubMed - indexed for MEDLINE]
Free Article
17.

Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.

Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A.

Am J Clin Oncol. 2002 Apr;25(2):140-8.

PMID:
11943891
[PubMed - indexed for MEDLINE]
19.

Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies.

Lee MJ, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, Kim ST, Park SH, Kang MH, Kang JH.

Cancer Res Treat. 2012 Dec;44(4):235-41. doi: 10.4143/crt.2012.44.4.235. Epub 2012 Dec 31.

PMID:
23341787
[PubMed]
Free PMC Article
20.

[Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].

Sagawa T, Sato Y, Takayama T, Kuroda H, Hirakawa M, Abe S, Iyama S, Sakamaki S, Kato J, Niitsu Y.

Gan To Kagaku Ryoho. 2007 Sep;34(9):1467-71. Japanese.

PMID:
17876148
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk